The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...
The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...
Metastatic castration-resistant prostate cancer (mCRPC) is a type of advanced prostate cancer that has spread to other parts of the body. It no longer responds to treatments that block testosterone, a ...
Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of ...
Results suggest bone-protecting agents should be used in patients with metastatic castration-resistant prostate cancer and bone metastasis, especially in the era of androgen receptor pathway ...
Zacks Investment Research on MSN
JNJ gets EU nod for expanded use of Akeega in prostate cancer
J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...
TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...
Clonal hematopoiesis of indeterminate potential (CHIP) is the presence of acquired somatic gene mutations in hematopoietic cells without an apparent blood disorder. CHIP is age-related and more common ...
Janux Therapeutics' leading candidate, JANX007, shows high efficacy and safety in Phase 1 trials for metastatic castration-resistant prostate cancer, targeting a multi-billion dollar TAM. Janux’s ...
Executives from Oric Pharmaceuticals (NASDAQ:ORIC) used a conference discussion to highlight near-term clinical catalysts for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results